Clinical trial NCT03902600: A Study of Photon and Proton Chemoradiotherapy As Definitive or Neoadjuvant Therapy in Non-Metastatic Pancreatic Cancer
Official title: Moderately Hypofractionated Photon and Proton Chemoradiotherapy As Definitive or Neoadjuvant Therapy in Non-metastatic Pancreas Cancer with Assessment of Treatment Response Utilizing Molecular Biomarkers
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Pancreatic Cancer
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2019-04-04
Enrollment: 103
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients with pancreatic cancer

Brief summary: This study will observe side effects for patients who receive a 3-week course of radiation and chemotherapy for pancreas cancer. Blood samples will be collected before and after treatment to assess pancreas cancer DNA levels and its impact on outcomes.


Eligibility criteria: Inclusion Criteria: -Age ≥ 18 years

* Histological confirmation of adenocarcinoma of the pancreas (head, body, or tail of pancreas)
* Imaging consistent with T1-4, N0-2, M0 pancreas cancer, including potentially resectable, boarderline resectable, or unresectable disease as per NCCN classification. When CT of the chest, abdomen, and pelvis are performed, this must be with contras per pancreas protocol. Imagining with a PET/MRI alone is acceptable on study. If a PET/CT is performed, a separate pancreas protocol CT is required for inclusion.
* Must have received neoadjuvant chemotherapy at the discretion of medical oncology
* Medical oncology consultation to confirm that patient is an appropriate candidate for concurrent chemotherapy and surgical oncology consultation for confirmation of resection status.

Note: Patients who have received previous chemotherapy for pancreatic cancer are allowed to participate in this study, unless they experienced a previous allergic reaction to the drugs used in this study.

* Planned to receive CRT, consisting of PBT or IMRT (45 Gy/15 fractions) with concurrent chemotherapy with 5FU or Capecitabine.
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 or Karnofsky Performance Status 70-100 (Appendix III).
* Willing to sign consent onto the Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking study, IRB 15-000136
* Patients do not need to agree to Biobank blood draw.
* Patients at Mayo Clinic Arizona are not required to consent to the Registry.
* Willing to sign consent for blood collection onto the Pancreas SPORE, IRB 354-06.
* Able to complete standard of care clinical questionnaire(s) by themselves or with assistance.

Exclusion Criteria:

* Presence of non-regional nodal involvement or distant metastatic disease (M1)
* Prior RT to the thorax, abdomen, or pelvis
* History of prior malignancy \< 2 years of enrollment, except non-melanotic skin cancer or carcinoma-in-situ of the cervix
* Immunocompromised patients and patients known to be HIV positive and not currently receiving antiretroviral therapy.

Note: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial.

* Receiving any investigational agent concurrent with CRT which would be considered as a treatment for the primary neoplasm.
* Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects:

  * Pregnant women
  * Nursing women
  * Men or women of childbearing potential who are unwilling to employ adequate contraception
* Co-morbid systemic or psychiatric illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

Primary outcomes:
measure: Acute grade 3 or higher GI AEs
timeFrame: 2 years after CRT
Secondary outcomes:
measure: late grade 3 or higher GI AEs
timeFrame: 2 years after CRT
measure: local-regional recurrence
timeFrame: 2 years after CRT
measure: progression free survival (PFS)
timeFrame: 2 years after CRT
measure: overall survival
timeFrame: 2 years after CRT or until death
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: Mayo Clinic in Arizona
state: Arizona
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic in Rochester
name: Kenneth W. Merrell, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Mayo Clinic in Rochester
name: Krishan R. Jethwa, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Mayo Clinic
name: Terence T. Sio, MD, MS
role: PRINCIPAL_INVESTIGATOR
References: